Business development is a vital part of our corporate strategy. BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The company’s… BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The company’s… About BioXcel Therapeutics, Inc. BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes artificial intelligence to identify improved therapies in neuroscience and immuno-oncology. Shares of clinical-stage biotech BioXcel Therapeutics (NASDAQ:BTAI) are down by 9.9% as of 11:58 a.m. EDT on Friday, after the company released its … We constantly seek strategic collaborations with companies and academia to enhance value and complement BTI’s programs, including:Clinical combination with BXCL701 with other I/O and targeted agents including but not limited to CAR-T and cancer vaccinesRegional commercialization rights for BXCL501 and BXCL701 programsWe are interested in investigational molecules with established clinical safety data that complement our pipeline and therapeutic areas.To inquire about collaborative opportunities with BTI, please contact our business development team The company’s… NEW HAVEN, Conn., June 23, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced the appointment of Reina Benabou, M.D., Ph.D., as Senior Vice President and Chief Development Officer (CDO).
Pipeline Prospector delivers free access to a database of drugs under clinical trials which made headlines done by BioXcel Therapeutics
The company’s two most advanced clinical development programs are BXCL501, an investigational sublingual thin film formulation of Dexmedetomidine in development for acute treatment of agitation resulting from neuropsychiatric disorders, and BXCL701, an orally administered systemic innate immunity activator in development for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer in combination with other immuno-oncology agents. BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The company’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The pipeline products of the company are BXCL501, and BXCL701.
Company Contact BioXcel Therapeutics, Inc. 555 Long Wharf Drive 12th Floor New Haven, CT 06511 United States T: 475-238-6837 BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology.